Informazione Regolamentata n. 20343-34-2026	Data/Ora Inizio Diffusione 24 Novembre 2026 08:15:15	Euronext Growth Milan

Societa'	:	OTOFARMA
Utenza - referente	:	OTOFARMAESTN01 - Incarnato Bartolomucci Anna
Tipologia	:	3.1
Data/Ora Ricezione	:	24 Novembre 2026 08:15:15
Data/Ora Inizio Diffusione	:	24 Novembre 2026 08:15:15
Oggetto	:	Otofarma: from November 18, 2026, shares are also traded on the Frankfurt stock exchange

Testo del comunicato

Vedi allegato

Teleborsa: distribution and commercial use strictly prohibited

press release

Otofarma: from November 18, 2026, shares are also traded on the Frankfurt stock exchange

Access to the German market expands the opportunities for trading the security and enhances its visibility within the international financial community

Naples, November 24, 2026 – Otofarma S.p.A**.** (Ticker: OTO), a company listed on Euronext Growth Milan and active in the design, production, and marketing of hearing aids and in offering innovative audiological services, announces that, starting from November 18, 2026, its ordinary shares are also traded on the Frankfurt Stock Exchange (Börse Frankfurt), within the Open Market segment (*Freiverkehr*).

The shares are identified on the German market by the code **WKN A41FFX**, with the symbol **5CW**, and retain the same ISIN code **IT0005663361** already used on Euronext Growth Milan.

The availability of the title on the Frankfurt financial center expands access to Otofarma shares for German investors and other international investors operating through the German market, enhancing the Group's visibility within the European financial community.

The expansion of trading venues is part of the broader process of enhancing Otofarma's presence in financial markets, helping to create conditions for a progressive expansion of the pool of potential investors and for greater diversification of the shareholder base.

Trading on the German market is alongside that on Euronext Growth Milan, which remains the reference market for Otofarma stock.

Title information

1. Euronext Growth Milan: OTO
2. Frankfurt Stock Exchange: 5CW
3. German identification code (WKN): A41FFX
4. ISIN: IT0005663361
5. Start of negotiations in Germany: November 18, 2026

***

The Otofarma SpA Group is a leader in the design, production, and marketing of personalized hearing aids in the Pharmacies channel. It has built its reputation on technological innovation and continuous research, offering advanced audiological solutions at a guaranteed democratic price, with the goal of making access to hearing care more equitable and widespread.
A pioneer in telemedicine, Otofarma was the first company in Europe to introduce specialist teleaudiology in pharmacies: today it directly manages this service in over 4,000 affiliated pharmacies, facilitating access to diagnosis and prosthesis customization.

Teleborsa: distribution and commercial use strictly prohibited

Founded by Gennaro Bartolomucci, now President and CEO, the company holds IT and instrumental patents. Its devices and services are distributed exclusively through partner pharmacies, guaranteeing a controlled and quality-oriented model.

For more information:

Otofarma S.P.A.- Investor relations
Anna Incarnato Bartolomucci
E-mail: anna.incarnato@otofarma.it
mob: +39 347 0506780

My Twin Communication S.r.l. - Investor relations Advisor
info@mytwincommunication.com
Mara Di Giorgio | +39 335 7737417
Federico Caretti | +39 334 3240282
Federico Bagatella | +39 331 8007258

Alantra – Euronext Growth Advisor
E-mail: ega@alantra.com
mob: +39 334 6267242

SEC Newgate – Media relations
Michele Bon – michele.bon@secnewgate.it – 338 693 3868
Francesca Brambilla – francesca.brambilla@secnewgate.it – 338 627 214

Fine Comunicato n.20343-34-2026	Numero di Pagine: 4